Ruxolitinib + Mao Inhibitors Interaction
Majorinteraction on record
Description
Strong inhibitors of CYP3A4 may increase ruxolitinib systemic concentrations and increase risk of adverse reactions. Concomitant use should be avoided.
Mechanism
Inhibition of CYP3A4-mediated metabolism of ruxolitinib
Source: NLP:ruxolitinib